Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone
Sponsor: Loma Linda University
A observational or N/A phase clinical study on Amyotrophic Lateral Sclerosis, this trial is actively recruiting participants. The trial is conducted by Loma Linda University and has accumulated 14 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Jun 2025 — Present [monthly]
Recruiting
-
Nov 2024 — Jun 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 9 earlier versions
-
Feb 2023 — Jan 2024 [monthly]
Recruiting
-
Feb 2022 — Feb 2023 [monthly]
Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Recruiting
-
May 2021 — Dec 2021 [monthly]
Recruiting
-
Apr 2021 — May 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Mar 2020 — Nov 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Mar 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Loma Linda University
- Northwestern University
- Temple University
- Thomas Jefferson University
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .